In health matters, caution often proves the wisest course.
No Brasil, a tensão entre urgência e cautela se manifesta na decisão do Ministério da Saúde de suspender preventivamente a vacina da dengue do Instituto Butantan, após 42 reações adversas graves entre aproximadamente 500 mil vacinados. A medida não representa o fim de uma conquista — o país permanece pioneiro na oferta universal de vacina contra a dengue —, mas um momento de pausa reflexiva diante da responsabilidade que acompanha qualquer avanço em saúde pública. Enquanto a vacina da Takeda segue disponível, o Brasil equilibra o peso de dois anos de progresso expressivo contra a doença com a obrigação ética de investigar cada sinal de risco antes de prosseguir.
- Duas mortes estão sob investigação e 42 reações graves foram notificadas, criando pressão imediata sobre as autoridades para agir antes que a causalidade fosse sequer confirmada.
- A suspensão da vacina do Butantan interrompe uma campanha de vacinação pública que havia contribuído para uma queda de 75% nos casos de dengue em 2025 em relação ao ano anterior.
- A vacina Qdenga da Takeda segue sendo aplicada sem interrupção, mas seu custo — até R$ 980 o esquema completo na rede privada — expõe a desigualdade de acesso enquanto a alternativa pública está paralisada.
- O Instituto Butantan defende a eficácia comprovada de sua vacina e promete revisão rigorosa, com possível retomada das aplicações no início de 2027.
- Autoridades reforçam que o combate ao Aedes aegypti continua sendo a base da prevenção, independentemente do status das vacinas.
O Brasil chegou a 2026 com duas vacinas capazes de proteger contra os quatro sorotipos do vírus da dengue: a desenvolvida pelo Instituto Butantan e a Qdenga, produzida pela japonesa Takeda. Em junho, porém, apenas uma delas seguia sendo aplicada.
O Ministério da Saúde, em conjunto com a Anvisa, suspendeu preventivamente a vacina do Butantan após o registro de 42 casos de reações adversas graves entre cerca de 500 mil vacinados. Duas mortes estão sendo investigadas por possível relação com o imunizante, embora a causalidade ainda não tenha sido estabelecida. O ministro Alexandre Padilha justificou a decisão com uma lógica simples: em saúde, a precaução é sempre prioritária.
A Qdenga, por sua vez, continuou sendo administrada sem interrupções. Na rede privada, o esquema completo de duas doses custa até R$ 980. O imunizante foi incorporado ao sistema público em fevereiro de 2024, inicialmente nos municípios com maior transmissão. Desde então, o país registrou uma queda de 75% nos casos de dengue em 2025 — de 6,6 milhões para 1,7 milhão de ocorrências —, consolidando o Brasil como o primeiro país do mundo a oferecer vacina contra a dengue pelo sistema universal de saúde.
O Butantan reconheceu a suspensão e comprometeu-se a conduzir uma revisão rigorosa do perfil de segurança de sua vacina. O instituto destacou eficácia de 79,6% no geral e 89% contra casos graves, além de resultados positivos nos municípios onde campanhas de vacinação em massa foram realizadas. Se a análise confirmar a segurança do imunizante, as aplicações poderão ser retomadas no início de 2027. Enquanto isso, as autoridades reforçam que eliminar os criadouros do Aedes aegypti continua sendo o pilar insubstituível da prevenção.
Brazil has two dengue vaccines capable of protecting against all four known strains of the virus—DENV-1, DENV-2, DENV-3, and DENV-4. One comes from the state-run Instituto Butantan. The other, called Qdenga, is made by Japan's Takeda pharmaceutical company. As of early June 2026, only one of them is being administered to the public.
The Health Ministry halted vaccinations with the Butantan shot in what officials described as a precautionary measure. The decision came after 42 cases of severe adverse reactions were reported among roughly 500,000 people who had received the vaccine. Two deaths are under investigation for possible connection to the shot, though health authorities have not yet established causality. Health Minister Alexandre Padilha explained the logic at a press conference in Brasília: in health matters, caution often proves the wisest course. The ministry and the National Health Surveillance Agency (Anvisa) made the announcement together.
The Takeda vaccine, by contrast, continues to be administered without interruption. In the private health system, a full course of Qdenga—two doses spaced 90 days apart—costs between 980 and 980 reais, with individual doses ranging from 390 to 490 reais. The vaccine is approved for people aged 4 to 60, whether they have never had dengue or have been infected before. It became available in Brazil's private clinics at the end of 2023 and was incorporated into the public health system in February 2024, initially in municipalities where dengue transmission was highest and vaccine supplies were most limited.
Brazil holds a distinction: it was the first country in the world to offer a dengue vaccine through a universal public health system. Since the Qdenga vaccine entered the public system, the Health Ministry has gradually expanded its vaccination strategy as more doses became available. The government reported in April that dengue cases had fallen 75 percent compared to the previous year. In 2025, Brazil recorded 1.7 million dengue cases—a sharp decline from the 6.6 million cases reported in 2024.
The Instituto Butantan, which developed its vaccine over years of research, issued a statement saying it would temporarily suspend vaccinations in line with guidance from the Health Ministry and Anvisa. The institute noted that the adverse reactions detected—three of which showed signs of severity—may or may not be connected to the vaccine itself. The pause is meant to ensure public safety as the vaccination campaign moves forward. Butantan emphasized that its vaccine demonstrated 79.6 percent overall efficacy and 89 percent efficacy against severe dengue in international peer-reviewed studies. In three municipalities where mass vaccination campaigns had taken place—Botucatu in São Paulo, Maranguape in Ceará, and Nova Lima in Minas Gerais—pharmacovigilance monitoring showed positive results with no significant adverse reactions in the broader population.
The institute committed to working with absolute rigor to gather more information about the vaccine's safety profile. If that review confirms the vaccine is safe, Butantan said, vaccinations could resume at the start of 2027 with full confidence for people served by the public system. Dengue itself remains one of Brazil's most significant viral threats, transmitted by the bite of infected female Aedes aegypti mosquitoes. Health authorities continue to stress that eliminating mosquito breeding grounds remains the cornerstone of prevention, vaccination or not.
Notable Quotes
In health matters, caution often proves the wisest course. Because of this, we are making a decision to discontinue the current strategy of using the Butantan vaccine.— Health Minister Alexandre Padilha
The Instituto Butantan will continue working with absolute rigor to deepen information about vaccine use so that, if safety is confirmed, vaccination can resume at the start of next year with full confidence for the SUS population.— Instituto Butantan statement
The Hearth Conversation Another angle on the story
Why did the government stop the Butantan vaccine but leave Takeda's alone?
The 42 severe reactions—and the two deaths under investigation—created enough uncertainty that officials decided to pause and investigate. With Takeda's vaccine, they apparently felt the safety data was solid enough to continue. It's a different risk calculus for each product.
But 42 cases out of 500,000 vaccinated—that's less than 0.01 percent. Why is that enough to halt a whole program?
The minister said it plainly: precaution. When you're vaccinating millions of people, even rare events matter. And when you have two potential deaths, you can't just keep going without understanding what happened. The political and public trust cost of ignoring that would be far worse.
So people who can afford it just buy Takeda's vaccine privately while the public system waits?
Exactly. For 980 reais—roughly a month's wages for many Brazilians—you can get protected now. Everyone else waits for Butantan to clear safety review, or they use Takeda through the public system if they live in a priority municipality. It's a two-tier system, at least temporarily.
The dengue numbers dropped 75 percent. Was that the vaccines working, or something else?
Probably both. The vaccines helped, but Brazil also had fewer cases overall in 2025 than 2024—1.7 million versus 6.6 million. That's a massive swing. The vaccination campaigns in those three cities showed clean safety data, so something was working. But now we don't know if that momentum continues without Butantan's vaccine in the mix.
When will people know if Butantan's vaccine is safe to use again?
The institute says early 2027, if the review goes well. But that's conditional. They're doing new studies and watching the people who were already vaccinated. If anything else emerges, that timeline could shift. For now, it's a waiting game.